Different roles for interleukin-4 during the course of Toxoplasma gondii infection

被引:103
作者
Roberts, CW
Ferguson, DJP
Jebbari, H
Satoskar, A
Bluethmann, H
Alexander, J
机构
[1] UNIV STRATHCLYDE, DEPT IMMUNOL, GLASGOW G4 0NR, LANARK, SCOTLAND
[2] JOHN RADCLIFFE HOSP, NUFFIELD DEPT PATHOL & BACTERIOL, OXFORD OX3 9DU, ENGLAND
[3] F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND
基金
英国惠康基金;
关键词
D O I
10.1128/IAI.64.3.897-904.1996
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The course of Toxoplasma gondii infection from initiation of disease perorally until day 28 postinfection was compared between interleukin-4 (IL-4) gene knockout (IL-4-/-) mice and their wild-type (IL-4+/+) counterparts on a disease-susceptible genetic background. The rate of mortality was significantly greater in mice deficient in IL-4 than in the immunocompetent controls, Although levels of T. gondii-specific spleen cell proliferation measured in vitro were similar between groups at all time points examined throughout infection, the quantities of cytokines released into the culture supernatant differed. Culture supernatants from spleen cells derived from IL-4-deficient mice contained significantly more gamma interferon than those derived from IL-4+/+ mice at day 7 postinfection, Conversely, IL-10 production was significantly greater from the spleen cells derived from wild-type mice at day 28 postinfection. Splenocytes from both groups of mice had a marked inhibition of proliferation in response to soluble tachyzoite antigen as well as reduced proliferation in response to concanavalin a between days 7 and 14 postinfection and marked proliferation on days 21 and 28 postinfection. At day 28 postinfection, histological examination of the brains indicated that IL-4+/+ mice had more severe pathological changes and more cysts than IL-4-/- mice. In addition, although many nonencysted single organisms were present in IL-4+/+ mice within both necrotic lesions and microglial nodules, few nonencysted parasites were found, and no necrotic lesions were present in IL-4-deficient animals. These results suggest that the observed reduction in mortality during the early acute phases of infection may be due to the down-regulatory effects of IL-4 or associated Th2-derived products on proinflammatory cytokines such as gamma interferon. However, the long-term effects of IL-4 are detrimental, possibly because of the ability of this cytokine to inhibit proinflammatory antiparasitic products. This may explain the increased parasite multiplication with cysts observed in the brains of IL-4+/+ mice.
引用
收藏
页码:897 / 904
页数:8
相关论文
共 58 条
[1]   INFLUENCE OF GENES WITHIN THE MHC ON MORTALITY AND BRAIN CYST DEVELOPMENT IN MICE INFECTED WITH TOXOPLASMA-GONDII - KINETICS OF IMMUNE REGULATION IN BALB H-2 CONGENIC MICE [J].
BLACKWELL, JM ;
ROBERTS, CW ;
ALEXANDER, J .
PARASITE IMMUNOLOGY, 1993, 15 (06) :317-324
[2]  
BLACKWELL JM, 1994, CLIN EXP IMMUNOL, V97, P107, DOI 10.1111/j.1365-2249.1994.tb06587.x
[3]   INDUCTION OF BRADYZOITE-SPECIFIC TOXOPLASMA-GONDII ANTIGENS IN GAMMA-INTERFERON-TREATED MOUSE MACROPHAGES [J].
BOHNE, W ;
HEESEMANN, J ;
GROSS, U .
INFECTION AND IMMUNITY, 1993, 61 (03) :1141-1145
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]  
BROWN CR, 1990, J IMMUNOL, V145, P3438
[6]   TEMPORAL DIFFERENCES IN THE EXPRESSION OF MESSENGER-RNA FOR IL-10 AND IFN-GAMMA IN THE BRAINS AND SPLEENS OF C57BL/10 MICE INFECTED WITH TOXOPLASMA-GONDII [J].
BURKE, JM ;
ROBERTS, CW ;
HUNTER, CA ;
MURRAY, M ;
ALEXANDER, J .
PARASITE IMMUNOLOGY, 1994, 16 (06) :305-314
[7]   ROLES OF GAMMA-INTERFERON AND OTHER CYTOKINES IN SUPPRESSION OF THE SPLEEN-CELL PROLIFERATIVE RESPONSE TO CONCANAVALIN-A AND TOXOPLASMA ANTIGEN DURING ACUTE TOXOPLASMOSIS [J].
CANDOLFI, E ;
HUNTER, CA ;
REMINGTON, JS .
INFECTION AND IMMUNITY, 1995, 63 (03) :751-756
[8]   MITOGEN-SPECIFIC AND ANTIGEN-SPECIFIC PROLIFERATION OF T-CELLS IN MURINE TOXOPLASMOSIS IS INHIBITED BY REACTIVE NITROGEN INTERMEDIATES [J].
CANDOLFI, E ;
HUNTER, CA ;
REMINGTON, JS .
INFECTION AND IMMUNITY, 1994, 62 (05) :1995-2001
[9]  
CHANG HR, 1990, IMMUNOLOGY, V69, P33
[10]  
CHAO CC, 1994, J IMMUNOL, V152, P1246